ClinicalTrials.gg
RecruitingNCT06625216SANIUpdated Apr 29, 2026

Severe Asthma Network Italy

An observational study in Severe Asthma, sponsored by Società Italiana di Allergologia, Asma e Immunologia Clinica. Recruiting at 1 site in Italy. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Società Italiana di Allergologia, Asma e Immunologia Clinica · Observational

How we know

From the registry’s dates

  • Started Feb 2017; still recruiting 9 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 177 studies in Asthma with a site in Italy — 20 open to participants now, 29 under way, 10 of them phase 3. Asthma · Italy.

Planned enrollment
4th of 47
5,000 · median 152
Started
2017
with 8 others
Observational
47 of 177
6 open now
Primary completion
2027-02
later than 13 of 28 live
Registered
159th of 177
by date

Among the 177 studies in Asthma with a site in Italy, this one is the 4th largest by planned enrollment of the 47 observational ones that give a count, is one of 9 that started in 2017, is one of 47 observational ones, reaches primary completion later than 13 of the 28 other live ones, and was the 159th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

20 of the 177 studies in Asthma with a site in Italy are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Asthma with a site in Italy, or all of them as a file.
02

Study summary

The goal of this registry is collecting data of severe asthma patients, recruited by specialized centers, in a real life setting, homogeneously placed on a database management system to follow them over the time.

The information recorded will provide:

  1. The collection of homogeneous clinical, functional and biologic data of patients with severe asthma in a real life setting.
  2. The evaluation of adherence to treatment in real life.
  3. The clinical eligibility of patients treated with biologics.
  4. The evaluation of patients' clinical response to each treatment.
  5. The monitoring of tolerability and safety.
  6. The long-term follow up of patients with severe asthma.
03

Conditions studied

  • Severe Asthma

Browse trials for

Keywords

  • Severe Asthma
  • Network
  • Registry
  • Biologics
  • Adherence
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients older than 12 years, diagnosed for severe asthma by a specialist, according to the ERS/ATS criteria, attending respiratory or allergy clinic for a scheduled visit are eligible for study enrollment. If inclusion/exclusion criteria are satisfied, a written consent to participate in the study will be obtained and an informative leaflet for the patient and his/her GPs will be delivered.

Eligibility criteria

Inclusion Criteria:

  1. signed and privacy disclaimer;
  2. age > 12 years;
  3. diagnosis of severe asthma according to the ERS/ATS criteria:

    1. During treatment with:

      • High-dose ICS + at least one addistional controller (LABA, montelukast, or theophylline) or
      • Oral >6 months/year
    2. at least one of the following occurs or would occur if treatment would be reduced:

      • ACT \<20 or ACQ>1.5
      • At least 2 exacerbations in the last 12 months
      • At least 1 exacerbation treated in hospital or requiring mechanical ventilation in the last 12 months
      • \<80% (if FEV1/FVC below the lower limit of normal)

Exclusion Criteria have not been considered in order to have a realistic view of severe asthma in real life.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Analyzing epidemiological and clinical characteristics of severe asthmatics from SANI registry.

    Collection of sociodemographic data: sex, employment, ethnicity, smocking habits.

    Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)

  2. Analyzing epidemiological and clinical characteristics of severe asthmatics from SANI registry.

    Collection of clinical data: age, age at asthma onset and/or age at asthma diagnosis (years).

    Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)

  3. Analyzing epidemiological and clinical characteristics of severe asthmatics from SANI registry.

    Collection of clinical data: weight (kilograms) and height (meters) combined to report Body Mass Index \[BMI\] in kg/m\^2.

    Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)

  4. Analyzing epidemiological and clinical characteristics of severe asthmatics from SANI registry.

    Collection of clinical data: presence of allergies and/or comorbidities, previous accesses to ER and/or hospitalizations, and numbers of exacerbations.

    Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)

  5. Collecting functional data of severe asthmatics from SANI registry.

    Assessment of lung function before and after a bronchodilator medication: Forced Vital Capacity \[FVC\] and Forced Expiratory Volume in 1 second \[FEV1\] values (liters) combined to report FEV1/FVC Ratio.

    Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)

  6. Collecting functional data of severe asthmatics from SANI registry.

    Assessment of lung function before and after a bronchodilator medication: Forced Vital Capacity \[FVC\] and Forced Expiratory Volume in 1 second \[FEV1\] values (percentages) combined to report FEV1/FVC Ratio.

    Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)

  7. Assessing inflammatory markers in order to characterize asthma endotypes.

    Measurement of Fractional exhaled Nitric Oxide \[FeNO\] (ppb).

    Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)

  8. Assessing inflammatory markers in order to characterize asthma endotypes.

    Measurement of total serum IgE (kU/L).

    Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)

  9. Assessing inflammatory markers in order to characterize asthma endotypes.

    Measurement of blood eosinophilia (10\^9 cells/L).

    Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)

  10. Assessing inflammatory markers in order to characterize asthma endotypes.

    Measurement of blood and sputum eosinophil levels (percentages).

    Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)

  11. Assessing asthma control and and PROs.

    Assessment of asthma control over time according to the GINA Guidelines and standardized questionnaires: Asthma Control Test \[ACT\], and Asthma Control Questionnaire \[ACQ\].

    Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)

  12. Assessing asthma control and and PROs.

    Assessment of the quality of life through Asthma Quality of Life Questionnaire \[AQLQ\] .

    Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)

  13. Studying the real life efficacy and safety of biologics.

    Evaluation of patients' clinical response to each biologics, reports of previous adverse reactions to the drug used and reasons for withdrawal from biologic treatment.

    Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy. 2012 May;42(5):650-8. doi: 10.1111/j.1365-2222.2011.03929.x. Epub 2012 Jan 18. PubMed 22251060 ↗
  • Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014 Feb;43(2):343-73. doi: 10.1183/09031936.00202013. Epub 2013 Dec 12. PubMed 24337046 ↗
  • De Ferrari L, Chiappori A, Bagnasco D, Riccio AM, Passalacqua G, Canonica GW. Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma? Expert Rev Respir Med. 2016;10(1):29-38. doi: 10.1586/17476348.2016.1111763. Epub 2015 Nov 13. PubMed 26566089 ↗
  • Latorre M, Baldini C, Seccia V, Pepe P, Novelli F, Celi A, Bacci E, Cianchetti S, Dente FL, Bombardieri S, Paggiaro P. Asthma Control and Airway Inflammation in Patients with Eosinophilic Granulomatosis with Polyangiitis. J Allergy Clin Immunol Pract. 2016 May-Jun;4(3):512-9. doi: 10.1016/j.jaip.2015.12.014. Epub 2016 Feb 13. PubMed 26883543 ↗
  • Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet. 2015 Sep 12;386(9998):1086-96. doi: 10.1016/S0140-6736(15)00157-9. PubMed 26383000 ↗
  • Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. doi: 10.1038/nrd3792. PubMed 23197041 ↗
  • Bagnasco D, Ferrando M, Bernardi S, Passalacqua G, Canonica GW. The path to personalized medicine in asthma. Expert Rev Respir Med. 2016 Sep;10(9):957-65. doi: 10.1080/17476348.2016.1205490. Epub 2016 Jul 11. PubMed 27399975 ↗
  • Chipps BE, Zeiger RS, Dorenbaum A, Borish L, Wenzel SE, Miller DP, Hayden ML, Bleecker ER, Simons FE, Szefler SJ, Weiss ST, Haselkorn T; TENOR Study Group. Assessment of asthma control and asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) observational cohort. Curr Respir Care Rep. 2012 Dec;1(4):259-269. doi: 10.1007/s13665-012-0025-x. Epub 2012 Sep 20. PubMed 23136642 ↗
  • Chipps BE, Zeiger RS, Borish L, Wenzel SE, Yegin A, Hayden ML, Miller DP, Bleecker ER, Simons FE, Szefler SJ, Weiss ST, Haselkorn T; TENOR Study Group. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol. 2012 Aug;130(2):332-42.e10. doi: 10.1016/j.jaci.2012.04.014. Epub 2012 Jun 12. PubMed 22694932 ↗
  • Schleich F, Brusselle G, Louis R, Vandenplas O, Michils A, Pilette C, Peche R, Manise M, Joos G. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med. 2014 Dec;108(12):1723-32. doi: 10.1016/j.rmed.2014.10.007. Epub 2014 Oct 27. PubMed 25456708 ↗
  • Ferry JJ, Horvath AM, Bekersky I, Heath EC, Ryan CF, Colburn WA. Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. J Clin Pharmacol. 1988 Jan;28(1):81-7. doi: 10.1002/j.1552-4604.1988.tb03105.x. PubMed 3350994 ↗
  • Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014 Jan 13;2014(1):CD003559. doi: 10.1002/14651858.CD003559.pub4. PubMed 24414989 ↗
  • Novelli F, Latorre M, Vergura L, Caiaffa MF, Camiciottoli G, Guarnieri G, Matucci A, Macchia L, Vianello A, Vultaggio A, Celi A, Cazzola M, Paggiaro P; Xolair Italian Study Group. Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy. Pulm Pharmacol Ther. 2015 Apr;31:123-9. doi: 10.1016/j.pupt.2014.09.007. Epub 2014 Sep 30. PubMed 25281265 ↗
  • Caminati M, Senna G, Guerriero M, Dama AR, Chieco-Bianchi F, Stefanizzi G, Montagni M, Ridolo E. Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address. Pulm Pharmacol Ther. 2015 Apr;31:28-35. doi: 10.1016/j.pupt.2015.01.006. Epub 2015 Jan 30. PubMed 25640019 ↗
  • Herland K, Akselsen JP, Skjonsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir Med. 2005 Jan;99(1):11-9. doi: 10.1016/j.rmed.2004.03.026. PubMed 15672843 ↗
  • Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma. Respir Med. 2013 Aug;107(8):1141-51. doi: 10.1016/j.rmed.2013.04.017. Epub 2013 May 28. PubMed 23721684 ↗
  • Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011 Jan;139(1):28-35. doi: 10.1378/chest.10-1194. Epub 2010 Aug 5. PubMed 20688929 ↗
  • Omalizumab Treatment for Adults and Children with Allergic Asthma: A Review of the Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Mar 9. Available from http://www.ncbi.nlm.nih.gov/books/NBK280029/ PubMed 25834884 ↗
  • Guida G, Scelo G, Friston DA, Blasi F, Heffler E, Paggiaro P, Carter V, Caminati M, Ricciardolo FLM, Senna G, Price DB, Canonica GW; SANI network. Longitudinal observation of severe asthma comorbidities and oral corticosteroids use from SANI and ISAR registries. World Allergy Organ J. 2026 Feb 26;19(3):101345. doi: 10.1016/j.waojou.2026.101345. eCollection 2026 Mar. PubMed 41783626 ↗
  • Ridolo E, Ottoni M, Nicoletta F, Locatelli F, Martinelli L, Maule M, Cheema NA, Blasi F, Paggiaro P, Heffler E, Brussino L, Canonica GW, Senna G, Caminati M; SANI network. Role of body anthropometry in severe asthmatic patients: Evidences from the Severe Asthma Network in Italy (SANI) registry. World Allergy Organ J. 2025 May 5;18(5):101056. doi: 10.1016/j.waojou.2025.101056. eCollection 2025 May. PubMed 40458738 ↗
  • Canonica GW, Blasi F, Paggiaro P, Heffler E, Braido F, Brussino L, Scioscia G, Cardini C, Oriecuia C, Sala I, Bagnardi V; SANI (Severe Asthma Network in Italy) study group. Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI). World Allergy Organ J. 2024 Dec 27;18(1):101016. doi: 10.1016/j.waojou.2024.101016. eCollection 2025 Jan. PubMed 39829953 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2017 (actual). Primary completion is estimated for Feb 2027, 120 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 120 months is above that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2024
First posted
Oct 3, 2024
StartActual
Feb 17, 2017
Primary completionEst.
Feb 17, 2027
CompletionEst.
Feb 17, 2037
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06625216
Lead sponsor
Società Italiana di Allergologia, Asma e Immunologia Clinica
Collaborators
Societa Italiana di Pneumologia
Responsible party
Sponsor
First posted
Oct 3, 2024
Start date
Feb 17, 2017
Primary completion
Feb 17, 2027 (estimated)
Completion
Feb 17, 2037 (estimated)
Last update
Apr 29, 2026

Study contacts

Enrico Marco Heffler, MD, PhD
Contact
enrico.heffler@hunimed.eu
0282241 ext. +39
Concetta Sirena
Contact
concetta.sirena@infomed-online.it
3420790871 ext. +39
Enrico Marco Heffler, MD, PhD
study chair · Personalized Medicine, Asthma and Allergy - IRCCS Humanitas Research Hospital, Rozzano, Italy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion